© 2020 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Expert Interviews
Tackling Secondary Progressive Multiple Sclerosis Early on Benefits Patients in a Number of Ways
December 04, 2020
Thomas P. Leist, MD, PhD, discusses secondary progressive MS, more specifically how very early control of the disease gives the patient the best chance for long term stability and gives the patient, the best chance of not entering the secondary state.
Determining SPMS as Biological Instead of Classification
December 03, 2020
Fred Lublin, MD, says it's possible health professionals can develop some biomarkers and find some differences in advanced MRI metrics in finding Secondary Progressive Multiple Sclerosis.
Secondary Progressive Multiple Sclerosis: Patient Burden and QOL
November 11, 2020
Thomas P. Leist, MD, PhD, discusses secondary progressive MS, particularly how patients that have less control have negative psychological effects.
Secondary Progressive Multiple Sclerosis: Managed Care Implications
November 11, 2020
Fred Lublin, MD, discusses the importance of clinical trial data and the what the language in drug labeling defines broad treatment possibilities.
Comorbidities in Older Patients
November 11, 2020
Thomas P. Leist, MD, PhD, describes different patient profiles and how they affect comorbidities, especially in older patient populations.
Clinical Features of Secondary Progressive Multiple Sclerosis
November 11, 2020
Fred Lublin, MD, describes how patients gradually worsen independent of relapse and the challenges of diagnosing and characterizing the SPMS.
Amwell in Favor of Extending Waivers Made for Reimbursable, Easy Access Telehealth Visits
November 10, 2020
In this second of a two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says he is in favor of extending CMS waivers that made telehealth visits reimbursable and easy for patients and providers.
Amwell, the ‘Intel Inside’ Telehealth Company
November 06, 2020
In this first of two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says the Boston-based telehealth company typically white labels its software to a client’s brand.
Otis Brawley: Certain Cancer Screening Tests Have Exacerbated Health Disparities
November 02, 2020
The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.
Otis Brawley: It’s Gotten Better but Problems With Cancer Screening Haven’t Gone Away
October 22, 2020
“Lung cancer screening is a great example of the problem,” says the former chief medical and scientific officer for the American Cancer Society in this third of four-part video series.